JP2024088642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024088642A5 JP2024088642A5 JP2024037589A JP2024037589A JP2024088642A5 JP 2024088642 A5 JP2024088642 A5 JP 2024088642A5 JP 2024037589 A JP2024037589 A JP 2024037589A JP 2024037589 A JP2024037589 A JP 2024037589A JP 2024088642 A5 JP2024088642 A5 JP 2024088642A5
- Authority
- JP
- Japan
- Prior art keywords
- segment
- modification
- edited
- composition
- editing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004048 modification Effects 0.000 claims 19
- 238000012986 modification Methods 0.000 claims 19
- 235000000346 sugar Nutrition 0.000 claims 13
- 108091034117 Oligonucleotide Proteins 0.000 claims 5
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 150000008163 sugars Chemical class 0.000 claims 2
- -1 -OMe sugars Chemical class 0.000 claims 1
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- 101710154606 Hemagglutinin Proteins 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 102000005348 Neuraminidase Human genes 0.000 claims 1
- 108010006232 Neuraminidase Proteins 0.000 claims 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 1
- 101710176177 Protein A56 Proteins 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 239000000185 hemagglutinin Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333004P | 2016-05-06 | 2016-05-06 | |
| US62/333,004 | 2016-05-06 | ||
| US201662410487P | 2016-10-20 | 2016-10-20 | |
| US62/410,487 | 2016-10-20 | ||
| JP2021070537A JP2021119776A (ja) | 2016-05-06 | 2021-04-19 | プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法 |
| JP2022167056A JP2023011676A (ja) | 2016-05-06 | 2022-10-18 | プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022167056A Division JP2023011676A (ja) | 2016-05-06 | 2022-10-18 | プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024088642A JP2024088642A (ja) | 2024-07-02 |
| JP2024088642A5 true JP2024088642A5 (enExample) | 2025-03-07 |
Family
ID=60203506
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558207A Active JP6872560B2 (ja) | 2016-05-06 | 2017-05-05 | プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法 |
| JP2021070537A Pending JP2021119776A (ja) | 2016-05-06 | 2021-04-19 | プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法 |
| JP2022167056A Pending JP2023011676A (ja) | 2016-05-06 | 2022-10-18 | プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法 |
| JP2024037589A Pending JP2024088642A (ja) | 2016-05-06 | 2024-03-11 | プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558207A Active JP6872560B2 (ja) | 2016-05-06 | 2017-05-05 | プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法 |
| JP2021070537A Pending JP2021119776A (ja) | 2016-05-06 | 2021-04-19 | プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法 |
| JP2022167056A Pending JP2023011676A (ja) | 2016-05-06 | 2022-10-18 | プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190300872A1 (enExample) |
| EP (2) | EP3452055A4 (enExample) |
| JP (4) | JP6872560B2 (enExample) |
| CN (1) | CN109414449A (enExample) |
| CA (1) | CA3022319A1 (enExample) |
| WO (1) | WO2017193053A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| JP6997623B2 (ja) * | 2014-12-12 | 2022-02-04 | エム. ウルフ、トッド | オリゴヌクレオチドを利用して細胞内の核酸を編集するための組成物および方法 |
| IL258821B (en) | 2015-10-23 | 2022-07-01 | Harvard College | Nucleobase editors and their uses |
| WO2017193053A1 (en) * | 2016-05-06 | 2017-11-09 | Woolf Tod M | Improved methods for genome editing with and without programmable nucleases |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| JP7588390B2 (ja) | 2016-10-14 | 2024-11-22 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 核酸塩基エディターのaav送達 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| BR112019019655A2 (pt) | 2017-03-23 | 2020-04-22 | Harvard College | editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物 |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| BR112020013848A2 (pt) | 2018-01-08 | 2020-12-01 | Iovance Biotherapeutics, Inc. | métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição |
| WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| AU2019255725A1 (en) * | 2018-04-18 | 2020-12-10 | Ligandal, Inc. | Methods and compositions for genome editing |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3942042A1 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| EP3956349A1 (en) | 2019-04-17 | 2022-02-23 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US20210079387A1 (en) * | 2019-08-27 | 2021-03-18 | The Jackson Laboratory | Cleavage-resistant donor nucleic acids and methods of use |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| EP4103740A1 (en) * | 2020-02-10 | 2022-12-21 | Palogen, Inc. | Nanopore device and methods of detecting and classifying charged particles using same |
| CN111378051B (zh) * | 2020-03-25 | 2022-03-01 | 北京市农林科学院 | Pe-p2引导编辑系统及其在基因组碱基编辑中的应用 |
| WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CN116261461A (zh) * | 2020-07-30 | 2023-06-13 | 新加坡科技研究局 | 刺激细胞增殖的方法 |
| US20220056437A1 (en) * | 2020-08-19 | 2022-02-24 | Integrated Dna Technologies, Inc. | Methods and compositions for inhibition of crispr re-cleavage events |
| CN113637670A (zh) * | 2021-04-27 | 2021-11-12 | 中国药科大学 | 一种用于任意基因表达调控的组合物及方法 |
| CA3237003A1 (en) * | 2021-11-01 | 2023-05-04 | George Mcdonald Church | Dna revertase |
| WO2025101484A1 (en) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3023787A1 (de) | 1980-06-25 | 1982-01-21 | Studiengesellschaft Kohle mbH, 4330 Mülheim | Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| DK0452457T3 (da) | 1989-11-03 | 1998-03-02 | Univ Vanderbilt | Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener |
| US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| AU2522095A (en) | 1994-05-19 | 1995-12-18 | Dako A/S | Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| AU4948801A (en) | 2000-03-27 | 2001-10-08 | Univ Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| US6936467B2 (en) | 2000-03-27 | 2005-08-30 | University Of Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US8232383B2 (en) | 2002-02-20 | 2012-07-31 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US7452987B2 (en) | 2002-08-05 | 2008-11-18 | Silence Therapeutics Aktiengesellschaft (Ag) | Interfering RNA molecules |
| US7923547B2 (en) | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| JP4665758B2 (ja) | 2003-04-22 | 2011-04-06 | 国立大学法人九州大学 | チオヌクレオシド−s−ニトロシル誘導体 |
| WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| CN104975020B (zh) | 2008-02-11 | 2020-01-17 | 菲奥医药公司 | 经修饰的RNAi多核苷酸及其用途 |
| AU2009336191B2 (en) | 2008-12-18 | 2017-08-24 | Novo Nordisk A/S | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8309356B2 (en) | 2009-04-01 | 2012-11-13 | Yale University | Pseudocomplementary oligonucleotides for targeted gene therapy |
| CA2794187C (en) | 2010-03-24 | 2020-07-14 | Rxi Pharmaceuticals Corporation | Rna interference in ocular indications |
| EP2616543A1 (en) | 2010-09-15 | 2013-07-24 | Alnylam Pharmaceuticals, Inc. | MODIFIED iRNA AGENTS |
| US10555911B2 (en) | 2012-05-04 | 2020-02-11 | Yale University | Highly penetrative nanocarriers for treatment of CNS disease |
| SI3401400T1 (sl) * | 2012-05-25 | 2019-10-30 | Univ California | Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja |
| SI2852668T1 (sl) * | 2012-07-12 | 2016-09-30 | Proqr Therapeutics Ii B.V. | Oligonukleotidi za izvedbo spremembe v sekvenci tarčne molekule rna, prisotne v živeči celici |
| BR112015022829B1 (pt) * | 2013-03-15 | 2022-06-14 | Cibus Europe B.V. | Método para a introdução de uma mutação mediada por oligonucleobase de reparação de gene (gron) em uma sequência alvo de ácido desoxirribonucleico (dna) em uma célula vegetal |
| US9234213B2 (en) * | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| CA2930015A1 (en) | 2013-11-07 | 2015-05-14 | Editas Medicine, Inc. | Crispr-related methods and compositions with governing grnas |
| CN110003066B (zh) | 2013-11-18 | 2021-09-03 | 阿克丘勒斯治疗公司 | 用于rna递送的可电离的阳离子脂质 |
| US9840699B2 (en) * | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
| SG11201609211VA (en) * | 2014-03-05 | 2016-12-29 | Nat Univ Corp Univ Kobe | Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same |
| ES2974625T3 (es) * | 2014-03-14 | 2024-06-28 | Cibus Us Llc | Procedimientos y composiciones para aumentar la eficacia de la modificación génica dirigida mediante reparación génica mediada por oligonucleótidos |
| EP3800248A3 (en) * | 2014-04-18 | 2021-08-04 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| EP3186376B1 (en) * | 2014-08-27 | 2019-03-20 | Caribou Biosciences, Inc. | Methods for increasing cas9-mediated engineering efficiency |
| US20170233762A1 (en) * | 2014-09-29 | 2017-08-17 | The Regents Of The University Of California | Scaffold rnas |
| EP3561052A1 (en) * | 2014-10-15 | 2019-10-30 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for generating or maintaining pluripotent cells |
| JP6997623B2 (ja) * | 2014-12-12 | 2022-02-04 | エム. ウルフ、トッド | オリゴヌクレオチドを利用して細胞内の核酸を編集するための組成物および方法 |
| EP3322804B1 (en) * | 2015-07-15 | 2021-09-01 | Rutgers, The State University of New Jersey | Nuclease-independent targeted gene editing platform and uses thereof |
| WO2017193053A1 (en) * | 2016-05-06 | 2017-11-09 | Woolf Tod M | Improved methods for genome editing with and without programmable nucleases |
-
2017
- 2017-05-05 WO PCT/US2017/031381 patent/WO2017193053A1/en not_active Ceased
- 2017-05-05 CA CA3022319A patent/CA3022319A1/en not_active Abandoned
- 2017-05-05 CN CN201780038175.3A patent/CN109414449A/zh active Pending
- 2017-05-05 JP JP2018558207A patent/JP6872560B2/ja active Active
- 2017-05-05 EP EP17793489.0A patent/EP3452055A4/en not_active Ceased
- 2017-05-05 US US16/099,106 patent/US20190300872A1/en not_active Abandoned
- 2017-05-05 EP EP21210808.8A patent/EP4023228A1/en not_active Withdrawn
-
2021
- 2021-04-19 JP JP2021070537A patent/JP2021119776A/ja active Pending
-
2022
- 2022-10-18 JP JP2022167056A patent/JP2023011676A/ja active Pending
-
2024
- 2024-03-11 JP JP2024037589A patent/JP2024088642A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024088642A5 (enExample) | ||
| EP1937312B1 (en) | Chimeric oligomeric compounds for modulation of splicing | |
| JP2024038327A5 (enExample) | ||
| JP2023507521A (ja) | シュタルガルト病の処置におけるヌクレオチド脱アミノ化のためのアンチセンスオリゴヌクレオチド | |
| JP2024105284A5 (enExample) | ||
| JPWO2019237069A5 (enExample) | ||
| JPWO2019217784A5 (enExample) | ||
| CN101448945A (zh) | 用于诱导外显子跳跃的手段和方法 | |
| EP3643783A1 (en) | Compositions and methods for modulation of smn2 splicing in a subject | |
| JP2009514877A5 (enExample) | ||
| CN105452461B (zh) | 生长激素受体的调节剂 | |
| JP2018516091A5 (enExample) | ||
| JP2016530882A5 (enExample) | ||
| JP2009532392A5 (enExample) | ||
| JP2006502694A5 (enExample) | ||
| JP2005501557A5 (enExample) | ||
| JP2016520312A5 (enExample) | ||
| JPWO2020069296A5 (enExample) | ||
| JP2020503017A5 (enExample) | ||
| JP7553036B2 (ja) | snoRNAの発現抑制剤を有効成分とするがん増殖抑制剤 | |
| JP2006502243A5 (enExample) | ||
| WO2023205708A1 (en) | SITE SPECIFIC GENETIC ENGINEERING UTILIZING TRANS-TEMPLATE RNAs | |
| JP2019527549A5 (enExample) | ||
| JPWO2021188390A5 (enExample) | ||
| JPWO2023081687A5 (enExample) |